Study Information
Study Details
View study details on clinicaltrials.gov.
Locations
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
Description
A Randomized Phase II Trial of Salvage Radiotherapy with Standard vs Enhanced Androgen Deprivation Therapy (with Enzalutamide) in Patients with Post-Prostatectomy PSA Recurrences with Aggressive Disease Features
The primary goal of this study is to determine whether, in men with post-prostatectomy PSA (prostate specific antigen) recurrences with aggressive disease features, salvage radiotherapy (SRT) with enhanced androgen deprivation therapy (ADT), consisting of enzalutamide (MDV3100) and a GnRH analog, will improve progression-free survival compared to SRT with standard GnRH analog -based ADT.
Principal Investigator
Co-Investigator(s)
Seth A Rosenthal, Radiation Oncologist, Sivakumar Reddy, M.D., David S Yee, M.D., MPH
Funder
RTOG
Related Studies
Genomic Health Oncotype DX AR-V7
Investigators: Kristie A. Bobolis, M.D., Sivakumar Reddy, M.D., Vijay Suhag, M.D., Brian K. Kim, M.D, Kristin N. Arreola, M.D., Rajeswari Chellappah, M.D., David S Yee, M.D., MPH, Nitin Rohatgi, MD